<DOC>
	<DOCNO>NCT01987375</DOCNO>
	<brief_summary>This study open label , single institution , Phase 1 dose-escalation study determine safety profile cetuximab-IRDye800 use subject head neck squamous cell carcinoma ( HNSCC ) undergo surgery curative intent . Participants give dose approve head neck cancer drug ( Cetuximab ) along investigational study drug call Cetuximab-IRDye800 . Cetuximab-IRDye800 drug give prior surgery attache cancer cell appear make visible doctor use special camera operation . The investigator evaluate whether use study drug along special camera well identify cancer patient operate room .</brief_summary>
	<brief_title>Cetuximab IRDye800 Study Optical Imaging Agent Detect Cancer During Surgical Procedures</brief_title>
	<detailed_description>This study conventional 3+3 phase I study evaluate three escalate dose level intravenous infusion cetuximab-IRDye800 patient tolerate 100 mg test/loading dose unlabeled cetuximab part screen process . Two cohort add include 100 mg unlabeled test/loading dose cetuximab , include 10 mg test dose prior enrollment . One cohort 6 patient add include 100 mg unlabeled test/loading dose cetuximab fix 50 mg dose cetuximab-IRDye800 .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>1 . Biopsy confirm diagnosis squamous cell carcinoma head neck . 2 . Patients diagnose T stage , subsite within head neck schedule undergo surgical resection . Patients recurrent disease new primary allow . 3 . Planned standard care surgery curative intent squamous cell carcinoma 4 . Age ≥ 19 year 5 . Have life expectancy 12 week 6 . Karnofsky performance status least 70 % ECOG/Zubrod level 1 7 . Have acceptable hematologic status , coagulation status , kidney function , liver function include follow clinical result : Hemoglobin ≥ 9gm/dL Platelet count ≥ 100,000/mm3 Magnesium , potassium calcium great equal low limit normal range per institution normal lab value TSH &lt; 10 micro International Units/mL 1 . Received investigational drug within 30 day prior first dose cetuximabIRDye800 2 . Had within 6 month prior enrollment : MI , CVA , uncontrolled CHF , significant liver disease , unstable angina 3 . Inadequately controlled hypertension without current antihypertensive medication 4 . History infusion reaction cetuximab monoclonal antibody therapy . 5 . Women pregnant breast feed 6 . Patients grade 2 great reaction test/loading cetuximab dose . 7 . Evidence QT prolongation pretreatment ECG ( great 440 m male great 450 m female ) . 8 . Lab value opinion primary surgeon would prevent surgical resection . 9 . Patients receive Class IA ( quinidine , procanamide ) Class III ( dofetilide , amiodarone , sotalol ) antiarrhythmic agent . 10 . Patients TSH &gt; 11</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>HNSCC</keyword>
	<keyword>Imaging</keyword>
</DOC>